Log In

New? Register Here

AVEO Pharmaceuticals Inc.

75 Sidney Street

  • Main Phone: (617) 299-5000
  • Fax Number: (617) 995-4995
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Endorsements: None Provided
  • Announcements: 0


AVEO Pharmaceuticals, Inc. is a cancer therapeutics company discovering, developing and commercializing targeted cancer therapies. The Company s Human Response Platform, a method of building preclinical models of human cancer, provides the Company with insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. Tivozanib is the Company s lead product candidate, which the Company partnered with Astellas Pharma Inc. (Astellas) during the year ended December 31, 2011. Tivozanib is an inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. In January 2012, the Company announced data from its global, phase III clinical trial of tivozanib, a therapy for first-line treatment in renal cell carcinoma (RCC), which the Company refers to as the TIVO-1 study.


Not provided at this time


Not provided at this time


There are no company announcements at this time.

Company's Strengths and Specialties

There is no information provided at this time.